A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Lange, Christian M ^a,b   Bibert, Stephanie ^a   Kutalik, Zoltan ^a   Burgisser, Philippe ^a   Cerny, Andreas ^c   Dufour, Jean Francois ^d   Geier, Andreas ^e   Gerlach, Tilman J ^f   Heim, Markus H ^g   Malinverni, Raffaele ^h   Negro, Francesco ⁱ   Regenass, Stephan ^e   Badenhoop, Klaus ^b   Bojunga, Jörg ^b   Sarrazin, Christoph ^b   Zeuzem, Stefan ^b   Müller, Tobias ^j   Berg, Thomas ^k   Bochud, Pierre Yves ^a   Moradpour, Darius ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Ospedale Moncucco   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Division of Gastroenterology   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h Division of Gastroenterology Hôpital Neuchâtelois   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CYTOCHROME P450; CYTOCHROME P450 27B1; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PREVALENCE; RETROSPECTIVE STUDY; SEASONAL VARIATION; TREATMENT OUTCOME; VALIDATION STUDY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; AGED; CALCIFEDIOL; DEMOGRAPHY; FEMALE; GENE FREQUENCY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; SEASONS; TREATMENT OUTCOME; VITAMIN D; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84863769369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040159     Document Type: Article

References (38)

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW, (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513-521.
2. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, et al. (2009) Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16: 75-90.
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
5. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428.
8. Lange CM, Sarrazin C, Zeuzem S, (2010) Review article: specifically targeted anti-viral therapy for hepatitis C- a new era in therapy. Aliment Pharmacol Ther 32: 14-28.
9. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609.
10. Clark PJ, Thompson AJ, McHutchison JG, (2010) IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 106: 38-45.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
12. Lange CM, von Wagner M, Bojunga J, Berg T, Farnik H, et al. (2010) Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol 22: 1303-1307.
13. Lange CM, Zeuzem S, (2011) IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 55: 962-701.
14. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-129 e118.
15. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, et al. (2012) Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 55: 1038-47.
16. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, et al. (2010) Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51: 1158-1167.
17. Abu Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N, (2011) Vitamin D supplement improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 17: 5184-5190.
18. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, et al. (2011) Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 54: 887-893.
19. Bailey R, Cooper JD, Zeitels L, Smyth DJ, Yang JH, et al. (2007) Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 56: 2616-2621.
20. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, et al. (2011) Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 60: 1624-1631.
21. Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, et al. (2009) Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 18: 2540-2548.
22. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, et al. (2011) High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377: 242-250.
23. Bouillon R, Auwerx J, Dekeyser L, Fevery J, Lissens W, et al. (1984) Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab 59: 86-89.
24. Rosen CJ, (2011) Clinical practice. Vitamin D insufficiency. N Engl J Med 364: 248-254.
25. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, et al. (2007) Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 36: 731-737.
26. Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt B, et al. (2011) Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 55: 322-327.
27. Clifton-Bligh RJ, Nguyen TV, Au A, Bullock M, Cameron I, et al. (2011) Contribution of a common variant in the promoter of the 1-alpha-hydroxylase gene (CYP27B1) to fracture risk in the elderly. Calcif Tissue Int 88: 109-116.
28. Reusch J, Ackermann H, Badenhoop K, (2009) Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res 41: 402-407.
29. Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, et al. (2010) Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum Genet 18: 1349-1352.
30. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, et al. (2001) Extrarenal expression of 25-hdydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86: 888-894.
31. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
32. Ramagopalan SV, Heger A, Berlanga AJ, et al. (2010) A ChiP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Research 20: 1352-1360.
33. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, et al. (2010) Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 11: 344-349.
34. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, et al. (2011) Complementary role of vitamin D deficiency and the IL-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology.
35. Milazzo L, Mazzali C, Bestetti G, Longhi E, Foschi A, et al. (2011) Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 9: 186-193.
36. Terrier B, Carrat F, Geri G, Pol S, Piroth L, et al. (2011) Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 55: 756-761.
37. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, et al. (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51: 655-666.
38. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, et al. (2002) Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 97: 2880-2885.